Alzchem Group Ag · XETR:ACT
Alzchem — Q3 2024 Earnings Presentation
36 slides from Alzchem's earnings presentation, Nov 7, 2024
Slide 1: Agile Science Pure Results
AGILE SCIENCE PURE RESULTS
Slide 2: Q3 2024 presenters and date
3 2024 ANDREAS NIEDERMAIER, CEO DR. GEORG WEICHSELBAUMER, CSO ANDREAS LOSLER, CFO November 7, 2024
Slide 3: Disclaimer
DISCLAIMER CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available info
Slide 4: Agenda — Analyst Presentation Q3 2024: Executive Summary
AGENDA — ANALYST PRESENTATION Q3 2024 Executive Summary
Slide 5: Highlights
HIGHLIGHTS Further growth in EBITDA also confirmed in Q 3 Group sales above Sales outlook 2024 confirmed but is previous year with strong expected in the lower range of the shifts between segments prediction NUTRITION NUTRITION Strong increase in EBITDA EBITDA outlook 2024 still valid due as a resul
Slide 6: Verbund System — Fully Integrated Business Model
© Alzchen Group AG / November 2024 “VERBUND” SYSTEM — FULLY INTEGRATED BUSINESS MODEL Ability to adapt production to meet changing end market needs Dormex’ “ DICYAN- C2) DIAMIDE ‘cunmoune ) aN \ CALCIUM G \ Cad” NITROGEN NiTRALz* ~ 7 Silzot ps sy ’ SEEEEEEene) C | S, RENEWABLE ne Infrastructure ENE
Slide 7: Verbund System — Step 1 Capacity Increase in Germany
“VERBUND” SYSTEM — FULLY INTEGRATED BUSINESS MODEL Step 1 — Capacity increase in Germany STEP 1 Dormex’ NITRO- GUANIDINE \ DICYAN- DIAMIDE 7™ /GUANIDINE- CALCIUM ‘SALTS CYANAMIDE aN CALCIUM, CARBIDE NITROGEN NiTRALz* AS) . 4 SESEEEEEID) C | RENEWABLE 7 Infrastructure ENE WADE CARBON ENERGY lzchen Gr
Slide 8: Verbund System — Step 2 New Production Plant in USA
“VERBUND” SYSTEM — FULLY INTEGRATED BUSINESS MODEL Step 2 — New production plant in USA STEP 1 Dormex’ DICYAN- DIAMIDE 7™ /GUANIDINE- CALCIUM ‘SALTS CYANAMIDE aN CALCIUM, CARBIDE NITROGEN NiTRALz* < 7 Silzot >? x 7 SESEEEEEID) C | RENEWABLE 7 Infrastructure ENE WADE CARBON ENERGY STEP 2 lzchen Group
Slide 9: Largest Investment in the Company's History
LARGEST INVESTMENT IN THE COMPANY'S HISTORY Alzchem to expand capacities in Germany and starts site selection in US MM steps w= step 2 end of 2026 024 end of 2026 end of 2029 ea lea Q— Ix S191 Major raw material for oro ope * Renew and expand the existing facilities * New production plant Capacity e
Slide 10: Agenda: Business and Financial Details
AGENDA — ANALYST PRESENTATION Q3 2024 ll. Business and financial details
Slide 11: Basics & Intermediates segment overview
NITRALZ® Berlka’ G CaD BASICS & INTERMEDIATES The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of
Slide 12: Basics & Intermediates Segment (in M€)
BASICS & INTERMEDIATES SEGMENT (in M€) Challenging market environment with positive EBITDA development SALES ANALYSIS Volume - 5.2% Q3 Q4. QI Q2- QB 4 QI 2 Q3 6.8% 2022 2022 2023 2023 2023 2023 2024 2024 2024 a > factor for the p: 8 4 A 2 B38 Wa Q Q@ 1-9 1-9 1-9 1-9 2022 2022 2023 2023 2023 2023 202
Slide 13: Specialty Chemicals segment overview
a oe CREAMINO Drmex' Bioselect®? DYHARD ##% Creapure‘ SPECIALTY CHEMICALS The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.
Slide 14: Specialty Chemicals Segment (in M€)
SPECIALTY CHEMICALS SEGMENT (in m€) Ongoing growth trend accompanied by profitability increase SALES ANALYSIS Q3 Q4. QI Q2- QB 4 QI 2 Q3 2022 2022 2023 2023 2023 2023 2024 2024 2024 devel behind Q3 04 QI Q2 Q3 4 QI 2 Q3 1-9 1-9 2022 2022 2023 2023 2023 2023 2024 2024 2024 2023 2024
Slide 15: Other & Holding segment overview
The "Other & Holding" segment offers infrastructure and energy supply services aad at our locations for the chemicals segments and for external customers. a, . OTHER & HOLDING
Slide 16: Other & Holding Segment (in M€)
OTHER & HOLDING SEGMENT (in me) Segment in line with Outlook ent: Q3 Q4. QI QZ QB 4 QI Q2- QB 2022 2022 2023 2023 2023 2023 2024 2024 2024 COMMENTS “Ss jpment in line with pass through o incr * EBITDA influenced by higher grid fees due to past Q3 Q4. QI Q2- QB 4 QI 2 Q3 1-9 1-9 2022 2022 2023 2023 2
Slide 17: Financial Overview
FINANCIAL OVERVIEW Continued growth in all major performance figures SALES (in M€) EBITDA (in M€) EBITDA margin (in %) Earnings per Share (in €) ith di ume ir EBITDA / 9) ntinuous EUR 7 EBITDA: Volume Price | d fin It led to an ir e in EPS of Currency
Slide 18: Balance Sheet (in M€)
BALANCE SHEET (in Mé€) Higher investment activity and strong equity ratio of 40% Other non-current assets Equity Deft d ti fe i isi wy age erered fares Tor pension provision Other non-current liabilities Inventories Pension provision Trade receivables Other current assets 6 114, Current liabilities
Slide 19: Cashflow (in M€)
CASHFLOW (in Mé€) Alzchem has a solid financial basis for upcoming growth investments investi
Slide 20: Outlook 2024 (in M€)
OUTLOOK 2024 (in me) EBITDA confirmed / sales confirmed but in the lower range of the corridor COMMENTS * Raised EBITDA outlook confirmed growth ected to increase to over 100 ME to approx. 570.0 ME D 5 S \ ment from half year figures Sales outlook for 2024 still valid but will probably end rowth A e
Slide 21: Financial Calendar
FINANCIAL CALENDAR ANN Upcoming dates* (ay NOV 13 2024 Minchner Kapitalmarkt Konferenz NOV 25-26 2024 Deutsches Eigenkapitalforum FEB 28 2025 Annual Report 2024 APR 30 2025 Quarterly Statement 1st Quarter 2025 MAY 8 2025 Annual General Meeting 2025 JUL 30 2025 Half-Year Financial Report 2025 OCT 30
Slide 22: Feedback
FEEDBACK We appreciate your feedback Were your expectations met? Are you missing any content? WE APPRECIATE YOUR FEEDBACK! QR-Code aera]
Slide 23: Alzchem Group Investor Relations
alzchem group Investor Relations T +49 8621 86-2888 F +49 8621 86-502888 ir@alzchem.com
Slide 24: Agenda: Back-Up
AGENDA — ANALYST PRESENTATION Q3 2024 lll. Back-Up
Slide 25: Balance Sheet
© Alzchem Group AG / November 2024 BALANCE SHEET Alzchem Group ALZCHEM GROUP (IN TE) 3112.2023 30.09.2024 Deviation ALZCHEM GROUP (IN TE} 31122023 30.09.2024 Deviation Intangible assets 2664 3.502 9% Share capital 101763 101.763 Tangible assets 17.281 185.482 £202 46% RETAINED EARNINGS (+) / LOSS (-
Slide 26: Pension Accounting (IFRS)
PENSION ACCOUNTING (IFRS) Alzchem Group (M€) IN FINANCIAL PENSION SERVICE NET INTEREST PENSION PENSION PENSION DEFERRED PENSION STATEMENT PROVISION costs costs PAYMENTS REMEASURE- PROVISION TAX ASSETS LIABILITY 31.12.2023 A MENTS 30.09.2024 30.09.2024 g FINAN RESULT BALANCE SHEET P&L CASHFLOW, Inter
Slide 27: Income Statement
© Alzchem Group AG / November 2024 INCOME STATEMENT Alzchem Group ALZCHEM GROUP (IN Te) oes nn oe aS sole oe a en Deviation (Q3) Revenue 750.432 126599 120824 142794 «150.064 13619 128.937 ans % Increase (+) / Decrease (-) in inventories of finished goods and work in progress O16 9.105 147 -13.972 6
Slide 28: Income Statement
© Alzchem Group AG / November 2024 INCOME STATEMENT Alzchem Group ALZCHEM GROUPIN TE) BB ovation 20) sees seliag Danton von Revense ‘ose 8857 Fe ierease | / Decrease (ninvntories fished goods and wekin progress 1 4310-487 <1000% tose = 1882 837 otter incone 3104 a6 a ee m3 40% Raw materials and cors
Slide 29: Cashflow Statement
© Alzchem Group AG / November 2024 CASHFLOW STATEMENT Alzchem Group Q3 3 1-9 1-9 CASHFLOW (IN Me} 2023 2024 2023 2024 ‘Consolidated earnings before taxes 12.035 17.393 32782 54495 Depreciation an fixed and intangible assets 6574 6402 19229 19290 Decrease in sension provisions 41 -5a7 1408 1651 Loss
Slide 30: Segment Overview by Quarter
SEGMENT OVERVIEW BY QUARTER AX Alzchem Group v SALES SALES o4 Deviation PY (Q3) Te Te % Basics & Intermediates “3344 -8%. Specialty Chemicals 10808 16% Other and Holding 649 9% Group Consolidation Alzchem Group, 139.193 133.200 136.191 EBITDA EBITDA Q2 O4 Deviation PY (Q3) Te Te Te % Basics & Interm
Slide 31: Alzchem Group Locations
ALZCHEM GROUP LOCATIONS Production sites and sales companies COVENTRY (UK) ATLANTA (USA) © Alzchem Group AG / November 2024 © SALES COMPANY
Slide 32: Implementing Operating Targets
© Alzchen Group AG / November 2024 IMPLEMENTING OPERATING TARGETS 2024 Focus on the key growth drivers and sustainability IMPROVEMENT * Pass on raw material price increases to the market * Flexibilization of production and processes * Volume growth & full capacity utilization GROWTH * Increase the a
Slide 33: Vertically Integrated Production Based on the NCN Chain
© Alzchem Group AG / November 2024 Vertically integrated production of chemical products based on the NCN chain “VERBUND” — FULLY INTEGRATED BUSINESS MODEL us O O Segment Specialty Chemicals Segment Basics & Inter- mediates BENEFITS OF “VERBUND” * Full control of product quality and specifications *
Slide 34: Our Products and Markets
© Alzchem Group AG / November 2024 OUR PRODUCTS AND MARKETS AN Successful with proven and new products in various industries (ay MAIN PRODUCTS DESCRIPTION END-MARKETS CREAMINO® = Anutritional additive for poultry and pigs Feed additive Creapure’ — Creapure®, premium brand for creatine monohydrate as
Slide 35: Our Products and Markets
© Alzchem Group AG / Novemeber 2024 OUR PRODUCTS AND MARKETS Successful with proven and new products in various industries n w = a < n ae a ta oo Wi [= e OTHER & HOLDING MAIN PRODUCTS DESCRIPTION END-MARKETS \N Calcium carbide-based mixtures for hot metal desulphurization Cad Steel industry Guanidin
Slide 36: Key Share Data
© Alzchem Group AG / Novemeber 2024 KEY SHARE DATA Share details as of November 5, 2024 SHARES OUTSTANDING. LAST CLOSING PRICE MARKET CAPITALIZATION TICKER WKN ISIN LISTING DESIGNATED SPONSOR 10,176,335 EUR 54.60 EUR 555.6m ACT A2YNT3 DEOOOA2YNT30 Frankfurt Stock Exchange — Prime Standard Baader Ban